statement of deviation or variation of funds, if any
AMANTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amanta Healthcare Limited has filed its quarterly statement confirming no deviation or variation in the utilisation of IPO proceeds for the quarter ended March 31, 2026. The company raised ₹126 crore through its Initial Public Offer listed on September 9, 2025. As of March 31, 2026, ₹4,766.36 lakh has been utilised out of ₹7,000 lakh allocated for the SteriPort manufacturing line, while the SVP manufacturing line allocation of ₹3,013.11 lakh remains unutilised. Issue expenses came in higher than estimated by ₹358.38 lakh, which was adjusted from the General corporate purposes allocation during Q2 FY26. The statement has been reviewed by the Audit Committee and the monitoring agency is CRISIL Ratings Limited.
No immediate impact on shareholders. The filing confirms that IPO funds are being deployed largely as per the disclosed objects, with the SteriPort project underway and SVP project not yet commenced. The higher issue expenses are a one-time adjustment.